This strategic approach not only facilitates the discovery of new bioactive scaffolds but also addresses a critical unmet need for alternative osteoclast-targeted therapies capable of restoring bone homeostasis in osteoporosis and other bone-resorptive disorders, while avoiding the adverse effects of conventional treatments such as bone osteolysis of bisphosphonates16osteonecrosis of jaw, hypocalcemia and atypical femur fractures in case of denosumab17and cardiovascular, musculoskeletal adverse effects of parathyroid hormone (PTH) analogs, such as teriparatide and abaloparatide18. The gene discussed is PTH; the disease is osteoporosis.